| Name | Title | Contact Details |
|---|
Estrie Roule Inc is a Granby, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In the simplest sense, we`re a company that creates solutions. More specifically, we design novel access device technology for neurovascular interventions and unmet clinical needs. Because in the precious seconds that surround a stroke emergency, clinicians need technology that delivers.
Meyer Distributing is a leader in automotive specialty products marketing and distribution. Through numerous strategically positioned warehousing facilities, Meyer serves thousands of customers nationwide with most states via Meyer Logistics direct ship.
At Proof, we believe that knowledge is power—and good health is a necessity. We`re a health technology and diagnostics company that is currently developing a cutting-edge, CRISPR-based platform for point-of-care facilities to test for COVID-19, with ambitions to transform in-home diagnostics across a broad spectrum of health applications in the future. Proof is the brainchild of Professor Feng Zhang, a world-renowned molecular biologist and leader of a research lab at the Broad Institute of MIT and Harvard. In early 2020, Dr. Zhang along with Dr. Jonathan Gootenberg and Dr. Omar Abudayyeh of the McGovern Institute pivoted their focus towards combating the emergent threat of the COVID-19 pandemic. Pioneers of the CRISPR gene-editing technology, the three scientists dropped everything to face the global public health crisis head on. Combining CRISPR and RT-LAMP technologies in a novel approach, our scientific team is developing a simple, streamlined molecular diagnostics platform that can quickly test for the presence of the SARS-CoV-2 virus. Intended for use within clinics, pharmacies, schools, workplaces and eventually homes, our easy-to-use, lab-quality test platform is undergoing rigorous R&D protocols so that we can provide fast, accurate diagnostics that will help communities take control of their health. We want to transform the anxiety of waiting days for COVID-19 test results into the peace of mind of quickly knowing what steps to take next. Our first test system, which we`re designing to detect SARS-CoV-2, will enable us to fulfill our mission of helping restore a degree of normalcy to our world. From there, we aim to transform personalized health, and expand our diagnostic platform to detect other diseases, with the goal of providing actionable health information that will allow people to lead better, healthier lives. If you`re with us, reach out today.
The Miromatrix Medical technology has the potential to enable the creation of fully biological replacement organs for the human body. In addition to the Company’s internal efforts focused on the development of its first product – a biological mesh for hernia repair – scientists around the globe are working with the Company’s technology and are taking critical steps toward the creation of human organs including the liver, lung, kidney, pancreas and heart. While our biological mesh development program has been conducted internally, our intent is for current and future products to be developed both at Miromatrix and in partnership with the best among those external groups already working with our technology in order to utilize this pre-existing expertise to develop individual products in the most efficacious, cost-effective and timely way possible.